RxDoctor Payments Data

Holly Clem, NP

Primary Care · Pulaski, TNNPI 1780008391

Payments from drug & device makers

$336in general payments, 2019–2025

Across 22 payments — averaging $15.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$79
  • Bayer$74
  • AbbVie$66
  • Amgen$43
  • Medtronic$26
  • Exact Sciences$18
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$336100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk5$79
Bayer5$74
AbbVie4$66
Amgen3$43
Medtronic2$26
Exact Sciences1$18
Lilly USA, LLC1$15
GSK1$15

How this compares

$336 in reported general payments places this provider in the 40th percentile of 189 primary care providers in Tennessee.

See all primary care providers in Tennessee

Medicare billing

Part B allowed, 2024
$49,258
Medicare patients
168
Services billed
1,697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$87,133
JardianceEmpagliflozin72$74,833
MounjaroTirzepatide30$35,797
EliquisApixaban47$33,471
RybelsusSemaglutide33$30,506
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$29,052
JanuviaSitagliptin Phosphate17$16,934
Spiriva RespimatTiotropium Bromide16$12,025
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$10,892
Breo ElliptaFluticasone/Vilanterol19$7,577
SymbicortBudesonide/Formoterol Fumarate27$7,387
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,244
KerendiaFinerenone11$6,911
Tresiba Flextouch U-100Insulin Degludec18$6,243
Combivent RespimatIpratropium/Albuterol Sulfate13$6,160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$79$117,638105 claims
GSKTrelegy Ellipta, Breo Ellipta$15$36,62965 claims
Lilly USA, LLCMounjaro$15$35,79730 claims
BayerKerendia$74$6,91111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 189 primary care providers in Tennessee.

Other primary care in Pulaski

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →